Forge Biologics to Present at Jefferies Gene Therapy / Editing Summit

Oct. 27, 2021 12:00 UTC



COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., Forge’s CEO, President, and Co-Founder, will deliver a company presentation at the Jefferies Gene Therapy / Editing Summit on Thursday, October 28, at 12:30 p.m. ET.

The conference will take place October 27-28, 2021 virtually. A live replay of the presentation will be available on the Jefferies conference website for 30 days following the presentation:

The Forge Biologics leadership team, including Dr. Miller; John Maslowski, Chief Commercial Officer; Christina Perry, Vice President of Finance and Investor Relations; and Magdalena Tyrpien, Vice President and Head of Business Development, will be available for 1:1 meetings virtually throughout the conference.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit


Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development

Client Development
John Maslowski
Chief Commercial Officer

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations


Source: Forge Biologics

Back to news